Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled dose-finding study of HW021199 tablets in idiopathic pulmonary fibrosis
CTR20232439Phase 2Active
- Sponsor
- Hubei Institute of Biopharmaceutical Industry
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HW021199 in idiopathic pulmonary fibrosis (IPF), sponsored by Hubei Institute of Biopharmaceutical Industry. Started Jan 2024; status: active.
02
Drugs
HW021199
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20232439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232439.